The FDA recently formally announced that it would exercise “enforcement discretion” for its rule that an Investigational New Drug (IND) permit be approved before fecal transplants could be used to treat Live-threatening infections with Clostridium Difficile bacteria.  While not changing written policy guidelines the FDA’s